Clinical trials
catalyst calendar across sponsors →Studies where SERA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional · 2 observational
Held by 4 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, Qube Research & Technologies Ltd, CITADEL ADVISORS LLC, TWO SIGMA INVESTMENTS, LP) · FINRA short interest 6.4 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 8 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEsNCT04301518Neonatal morbidity/mortalityRandomized · Open-label · Prevention | Not applicable | Active, not recruiting | Other: Multimodal intervention strategy | Preterm Labor, Preterm Birth | 6,500 | 2024-12-06actual | 2024-12-06 |
| A Multicenter Assessment of a Spontaneous Preterm Birth Risk PredictorNCT02787213observationalArea under the receiver operator characteristic curve (AUROC) for prediction of preterm versus term birth using freshly collected specimens. | — | Completed | — | Preterm Birth | 5,011 | Jun 2019actual | 2021-04-14 |
| Proteomic Assessment of Preterm BirthNCT01371019observationalSpontaneous Preterm Birth | — | Completed | — | Preterm Birth | 5,500 | Dec 2014actual | 2015-06-11 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19